Page 43 (Abstract), after the last line, beginning on a new page, please insert the attached Sequence Listing.

## **REMARKS**

Claims 1-29 are pending in the present application.

Applicants have now submitted a Sequence Listing and a corresponding computer-readable Sequence Listing. The sequence information recorded in the corresponding computer-readable Sequence Listing is identical to the paper copy of the Sequence Listing. Support for all of the sequences listed in the Sequence Listing is found in the present application as originally filed. No new matter is believed to have been introduced by the submission of the Sequence Listing and the corresponding computer-readable Sequence Listing.

Applicants submit that the present application is ready for examination on the merits.

Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon
Attorney of Record
Registration No. 24 61

Registration No. 24,618

Vincent K. Shier

Registration No. 50,552

Daniel Pereira 45,518

22850

Tel.: (703) 413-3000 Fax: (703) 413-2220

NFO:VKS

Docket No.: 216907US0X Serial No.: 10/014,670

## MARKED-UP COPY

## IN THE SPECIFICATION

Please amend Table 1 appearing on page 27 as follows:

TABLE 1: Oligonucleotides used to construct the Inc/cya chimeras described in this study. Restriction sites used for cloning are underlined.

Chimera	forward primer	reverse primer
IncA/mycHIS	TGACCTCGAGTTAACCTATTAAGGATAAAATT (SEO ID NO: 1)	GACTGAATTCGTTGCTCTATCTACGGGTGA (SEQ ID NO: 2)
IncB/mycHIS	GATCCTCGAGTTAATCTATTTTAGATAGG (SEQ ID NO: 3)	GACTGAATTCCTTGTTGTACGGACAGTAAT (SEQ ID NO: 4)
IncB	GATCCTCGAGTTAATCTATTTTAGATAGG (SEQ ID NO: 5)	CTAGGAATTCGATTGAACAGTAACAGATCC (SEQ ID NO: 6)
hydro/mycHIS IncA/cya	GACT <u>AAGCTT</u> GTAACCTATTAAGGATAAAATT (SEQ ID NO: 7)	GACT <u>TCTAGA</u> AATGATAACCTTTTCAATGAA <u>(SEQ ID NO: 8)</u>
IncB/cya	GACTAAGCTTGTAATCTATTTTAGATAGGAA (SEQ ID NO: 9)	GACTTCTAGATCCAGGTTTTTCGGAAGCAGA (SEQ ID NO: 10)
IncC/cya	GACTAAGCTTGTAAGTAAAAAACACAAAAAAT (SEQ ID NO: 11)	GACTTCTAGATATTTGAGCTGGTACAACAGG (SEQ ID NO: 12)
mutY/cva	GACTAAGCTTGCATTTGATAATTGCATAAA (SEQ ID NO: 13)	GACTTCTAGACGCTCGAGAATAATAACCC (SEQ ID NO: 14)
CP026/cva	GACTAAGCTTGAATACATAAGCTGTTC (SEQ ID NO: 15)	GACTTCTAGAAATGATTAGGTAAGCAATG (SEQ ID NO: 16)
CP146/cya	GACTAAGCTTAAAGTGTTTGAGATGAATT <u>(SEQ ID NO: 17)</u>	GACTTCTAGACGCTCCCAACCCCAGAGTC (SEQ ID NO: 18)
CP308/cya	GACTAAGCTTATTATAGACAGATTAAAAT (SEQ ID NO: 19)	GACTTCTAGACTTAAAAAATACCCAGGAACA (SEQ ID NO: 20)
   CP367/cya	GACTAAGCTTACAACAAATTAAGATATAATC (SEQ ID NO: 21)	GACTTCTAGATTTTATTTTAGCAATCAC (SEQ ID NO: 22)
CP585/cya	GACTAAGCTTGTAAATTGGAGATTGTAGTAGC (SEQ ID NO: 23)	GACTTCTAGAAACAATTGTATGATTCCATCC (SEQ ID NO: 24)

Page 43 (Abstract), after the last line, beginning on a new page, please insert the attached Sequence Listing